Dassault Systèmes is one of Europe’s largest software companies, and it is having an anxious year. Its shares are down about a quarter this year. It pushed out its chairman in February. And investors worry that a new wave of AI could hollow out its main business.
Its answer, announced on Thursday: spend up to $2 billion on a company most people have never heard of.
The French firm has agreed to buy ArisGlobal, a maker of drug-safety and regulatory software. The price is roughly $1.8 billion in cash, plus up to $200 million more tied to future AI revenue. The seller is Nordic Capital, a Swedish private-equity group that has owned it since 2019. The whole sum comes from Dassault’s own cash pile.
What Dassault is buying
ArisGlobal is not a household name, but it sits deep inside the pharmaceutical industry. Founded in 1989, it is based in Waltham, Massachusetts. It serves more than 200 customers, including half of the world’s 50 biggest drugmakers, plus biotechs and government health regulators. Its software processes more than 12 million patient safety reports a year. It expects revenue of about $175 million in 2026.
